Cellectis SA (NASDAQ:CLLS) Expected to Announce Quarterly Sales of $3.45 Million
Equities research analysts forecast that Cellectis SA (NASDAQ:CLLS) will announce sales of $3.45 million for the current quarter, Zacks Investment Research reports. Four analysts have provided estimates for Cellectis’ earnings, with the highest sales estimate coming in at $8.00 million and the lowest estimate coming in at $500,000.00. Cellectis reported sales of $2.19 million during the same quarter last year, which would indicate a positive year over year growth rate of 57.5%. The business is scheduled to issue its next quarterly earnings results on Tuesday, November 12th.
On average, analysts expect that Cellectis will report full-year sales of $14.27 million for the current fiscal year, with estimates ranging from $10.14 million to $22.40 million. For the next financial year, analysts anticipate that the firm will post sales of $48.30 million, with estimates ranging from $15.00 million to $82.00 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of research analysts that cover Cellectis.
Cellectis (NASDAQ:CLLS) last posted its quarterly earnings data on Tuesday, August 6th. The biotechnology company reported ($0.79) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.61) by ($0.18). Cellectis had a negative return on equity of 21.51% and a negative net margin of 813.06%. The company had revenue of $2.93 million for the quarter, compared to analysts’ expectations of $3.45 million.
Several hedge funds have recently added to or reduced their stakes in the company. OneAscent Financial Services LLC bought a new position in shares of Cellectis in the second quarter valued at approximately $257,000. D. E. Shaw & Co. Inc. bought a new position in shares of Cellectis in the second quarter valued at approximately $502,000. Cubist Systematic Strategies LLC bought a new position in shares of Cellectis in the second quarter valued at approximately $103,000. Point72 Asset Management L.P. boosted its position in shares of Cellectis by 66.9% in the second quarter. Point72 Asset Management L.P. now owns 142,500 shares of the biotechnology company’s stock valued at $2,223,000 after acquiring an additional 57,100 shares during the period. Finally, Marshall Wace LLP bought a new position in shares of Cellectis in the second quarter valued at approximately $772,000. Institutional investors own 31.95% of the company’s stock.
NASDAQ CLLS traded up $0.47 during trading hours on Friday, reaching $12.89. 4,692 shares of the company were exchanged, compared to its average volume of 112,600. Cellectis has a 1 year low of $11.70 and a 1 year high of $29.97. The business’s 50 day simple moving average is $14.67 and its 200-day simple moving average is $17.08. The company has a quick ratio of 8.46, a current ratio of 8.47 and a debt-to-equity ratio of 0.11. The stock has a market capitalization of $516.67 million, a P/E ratio of -6.68 and a beta of 1.72.
Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia (ALL); UCART22 to treat ALL and non-Hodgkin lymphoma (NHL); ALLO-501 for treating relapsed/refractory NHL; and UCART123 for the treatment of acute myeloid leukemia (AML) and blastic plasmacytoid dendritic cell neoplasm.
Featured Article: Hold Rating
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Cellectis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectis and related companies with MarketBeat.com's FREE daily email newsletter.